Dr. Mark Krul, Ph.D., is a seasoned biotech entrepreneur and investor with over 30 years of experience in oncology drug development. Dr. Krul co-founded Aglaia Oncology Funds in 2004, a venture capital firm dedicated to advancing anticancer therapies, and has since helped launch and invest in numerous biotechnology companies. He has co-founded or held leadership roles in multiple startups, including Inthera Bioscience AG (targeted cancer therapeutics) and Sapreme Technologies (macromolecule drug delivery), reflecting his focus on innovative cancer treatments. Dr. Krul also served on the boards of several biotech firms such as Merus (biclonal antibodies), MIMETAS (organ-on-a-chip technology) and Cristal Therapeutics (nanomedicine). His portfolio has achieved notable success with company exits, including the acquisition of Syntarga by Byondis and the Nasdaq IPO of Merus N.V., underscoring his track record in building value. Dr. Krul’s background in molecular biology and immunology underpins his strategic guidance in drug development, and he previously held research leadership posts at institutions like the NDDO Research Foundation and the European Cancer Center. He continues to bridge science and business in his current roles, notably as Chief Scientific Officer of the Oncode Accelerator program, and his work spans Europe (the Netherlands, Switzerland, the UK) and global markets as he drives innovations to international success.

Based in the Netherlands, Dr. Krul continues to bridge science and business, supporting Immunogenik’s mission to advance transformative immunotherapies for solid tumors and beyond.